BI-836901

N/A

Report date: 2025/01/26 19:23:27

Base Information

Drug NameBI-836901

Drug Alias Namenanobody therapeutics (Boehringer Ingelheim/Ablynx)BI-836901

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAngiopoietin-2 inhibitorsDelta-like protein 4 inhibitors

TargetsAngiopoietin-2Delta-like protein 4

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBoehringer Ingelheim Corp

China Registration ClassN/A

Develop Information

Active CompaniesAblynx Nv Boehringer Ingelheim Corp

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A